Conditions: Type 2 Diabetes
Keywords: Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Angiotensin Receptor Inhibitors Angiotensin-Converting Enzyme Inhibitors Antihypertensive Agents Cardiovascular Agents Pharmacological Actions
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2245
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied

Detailed description:

Arms:
arm 1: Dapagliflozin 10 mg tablets arm 2: Placebo tablets matching dapagliflozin tablets

Interventions: intervention 1: Dapagliflozin intervention 2: Placebo matching Dapagliflozin
Intervention descriptions: intervention 1: Tablets, Oral, 10 mg, once daily, Up to 12 weeks intervention 2: Tablets, Oral, 0 mg, once daily, Up to 12 weeks

Protocol document: